Navigation Links
Perrigo to Host Analyst Day on October 5, 2011 at the TASE, Tel Aviv Stock Exchange in Tel Aviv, Israel
Date:10/4/2011

ALLEGAN, Mich., Oct. 4, 2011 /PRNewswire/ -- Perrigo Company (Nasdaq: PRGO;TASE) today announced that Perrigo CFO Judy Brown and Senior Management will meet with analysts on Wednesday, October 5, 2011 at 9:30 a.m. (IST) at the TASE Headquarters at 54 Ahad Ha'am Street, Tel Aviv, Israel  

The day will include presentations on the Consumer Healthcare, Nutritionals, Rx, and API businesses, finance, sales and marketing, quality, and research and development.

Perrigo Company is a leading global healthcare supplier that develops, manufactures and distributes OTC and generic prescription (Rx) pharmaceuticals, infant formulas, nutritional products, active pharmaceutical ingredients (API) and pharmaceutical and medical diagnostic products. The Company is the world's largest store brand manufacturer of OTC pharmaceutical products and infant formulas. The Company's primary markets and locations of manufacturing and logistics operations are the United States, Israel, Mexico, the United Kingdom and Australia. Visit Perrigo on the Internet (http://www.perrigo.com).  


'/>"/>
SOURCE Perrigo Company
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Perrigo to Host Analyst Day on September 27, 2011 at the NASDAQ MarketSite in Times Square
2. Perrigo Announces FDA Final Approval for Ketoconazole Foam, 2%
3. Perrigo Company Will Release Fourth Quarter Fiscal 2011 Results on August 16, 2011
4. Watson Enters into Agreement to Acquire Products Related to Perrigos Acquisition of Paddock Laboratories
5. Perrigo Closes Acquisition of Paddock Labs
6. Perrigo Receives FDA Approval to Market Coated Cinnamon Nicotine Gum
7. Perrigo Provides Update on Acquisition of Paddock Labs
8. Perrigo Announces Launch of the Generic Version of Nasacort® AQ
9. Perrigo Company to Present at the Goldman Sachs 32nd Annual Global Health Care Conference
10. Perrigos Partner Synthon Receives FDA Tentative Approval for Levocetirizine Solution - Generic Equivalent to Xyzal® Oral Solution
11. Perrigo Announces FDA Final Approval for Ranitidine 150 - Generic Equivalent to Zantac 150®
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... , April 28, 2016  The blood testing market ... dollars, according to Kalorama Information and The Freedonia Group ... and nucleic acid testing.  The healthcare research firm said ... in developing blood collection stations and in improving testing ... Kalorama Information,s report, Blood Testing Market in ...
(Date:4/28/2016)... , April 28, 2016 Dr. ... and Ste phen ... ArisGlobal®, a leading provider of cloud-based software solutions for life ... Pharmacovigilance team to bring a wealth of insight to a growing ... pharmacovigilance knowledge. George Phillips joined ArisGlobal in ...
(Date:4/28/2016)... 28, 2016  ValGenesis, Inc., the market ... (VLMS) today announced that a prominent world ... of chronic kidney failure has selected ValGenesis ... corporate validation process. The global medical device ... to manage their validation processes electronically. Upon ...
Breaking Medicine Technology:
(Date:4/29/2016)... ... April 29, 2016 , ... ... flexibility in repaying their loans, more information about their loan terms and accounts, ... outstanding student loan debt, including federal and private loans, has reached $1.3 trillion, ...
(Date:4/29/2016)... ... April 29, 2016 , ... A ... born with severe congenital diaphragmatic hernia have better survival rates if surgery is ... hernia (CDH)—a condition where the diaphragm fails to form completely, letting abdominal organs ...
(Date:4/29/2016)... Kansas City, Missouri (PRWEB) , ... April 29, 2016 , ... ... Unlike traditional crutches which put pressure on the armpits, the M+D Crutch evenly distributes ... less strain on their wrists and hands when using the crutches than with other ...
(Date:4/29/2016)... ... 29, 2016 , ... Melanoma is the deadliest type of skin cancer. Although only about 1 ... skin cancer deaths. More than 10,000 people are expected to die of melanoma this year. ... is the one of the most commonly diagnosed cancers in young women. A recent breakthrough ...
(Date:4/29/2016)... ... ... Reltok Nasal Products proudly announces that Boston Medical Products, Inc., a leading ... specialty, has added the KOTLER NASAL AIRWAY™ to its diverse product line. , A ... safety device secured by nasal surgeons onto the floor of the nasal passages, at ...
Breaking Medicine News(10 mins):